Crossmark

Starting dose selection of palbociclib in Chinese patients with breast cancer based on population kinetic–pharmacodynamic model of neutropenia

Published Online: 2022-10-22

Published Print: 2022-12

Authors

Jian, Weizhe

Xue, Junsheng

Yao, Qingyu

Chen, Rong

Yao, Ye

Wang, Mopei

Zhou, Tianyan https://orcid.org/0000-0003-3238-2982
Funding

Funding for this research was provided by:

Peking University Medicine Seed Fund for Interdisciplinary Research (BMU2021MX003)

Wu Jieping Medical Foundation (320.6750.2020-20-34)
License Information

Text and Data Mining valid from 2022-10-22

Version of Record valid from 2022-10-22
More Information

Article History

Received: 4 May 2022

Accepted: 5 October 2022

First Online: 22 October 2022

Declarations

:

: The authors declare no conficts of interest in relation to this study.

Document is current